SCHEMBL5830969

SCHEMBL5830969

Cc1cc(-c2nnc(NS(=O)(=O)c3cccc(Cl)c3C)s2)ccc1F

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.52
HSD11B1 P28845 8/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
EDNRB P24530 2/20 0.43
EDNRA P25101 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HSD17B1 P14061 2/20 0.43
HSD17B2 P37059 2/20 0.43
SLC40A1 Q9NP59 1/20 0.41
AMY1A P0DUB6 1/20 0.41
TASP1 Q9H6P5 1/20 0.41
FSCN1 Q16658 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6623494 0.86 MEN1 (0.51) KDM1AHSD11B1MEN1KMT2ALMNA
SCHEMBL5391755 0.83 MEN1 (0.60) KDM1AHSD11B1MEN1KMT2ALMNA
SCHEMBL6622547 0.82 KMT2A (0.47) KDM1AHSD11B1MEN1KMT2ALMNA
SCHEMBL5389359 0.81 KDM1A (0.52) KDM1AHSD11B1MEN1KMT2ALMNA
SCHEMBL5830734 0.81 HSD11B1 (0.46) KDM1AHSD11B1EDNRBEDNRAHSD17B1
SCHEMBL2763006 0.81 KDM1A (0.61) KDM1AHSD11B1MEN1KMT2AHSD17B1
SCHEMBL6690238 0.79 SLC40A1 (0.46) HSD11B1EDNRBEDNRASLC40A1
SCHEMBL5831833 0.78 HSD11B1 (0.51) KDM1AHSD11B1MEN1KMT2ALMNA
SCHEMBL5398543 0.77 SLC40A1 (0.54) KDM1AHSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6611897 0.77 ACLY (0.44) HSD11B1EDNRBEDNRASLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 KDM1A 1842/4885HSD11B1 2/4885MEN1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.